The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

D. Przepiorka

Baylor College of Medicine

Center for Cell and Gene Therapy

The University of Texas M. D. Anderson Cancer Center

6565 Fannin Street

USA

[email]@bcm.tmc.edu

Name/email consistency: low

 
 
 
 
 
 
 

Affiliations

  • Baylor College of Medicine, Center for Cell and Gene Therapy, The University of Texas M. D. Anderson Cancer Center, 6565 Fannin Street, USA. 2001
  • Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX 77030, USA. 2000
  • Department of Blood and Marrow Transplantation, University of Texas, M.D. Anderson Cancer Center, Houston, USA. 1999
  • The University of Texas M.D. Anderson Cancer Center, Houston, USA. 1998

References

  1. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Przepiorka, D., Smith, T.L., Folloder, J., Anderlini, P., Chan, K.W., Körbling, M., Lichtiger, B., Norfleet, F., Champlin, R. Blood (2001) [Pubmed]
  2. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Przepiorka, D., Kernan, N.A., Ippoliti, C., Papadopoulos, E.B., Giralt, S., Khouri, I., Lu, J.G., Gajewski, J., Durett, A., Cleary, K., Champlin, R., Andersson, B.S., Light, S. Blood (2000) [Pubmed]
  3. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Przepiorka, D., Saliba, R., Cleary, K., Fischer, H., Tonai, R., Fritsche, H., Khouri, I.F., Folloder, J., Ueno, N.T., Mehra, R., Ippoliti, C., Giralt, S., Gajewski, J., Donato, M., Claxton, D., Braunschweig, I., van Besien, K., Anderlini, P., Andersson, B.S., Champlin, R. Biol. Blood Marrow Transplant. (2000) [Pubmed]
  4. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Przepiorka, D., van Besien, K., Khouri, I., Hagemeister, F., Samuels, B., Folloder, J., Ueno, N.T., Molldrem, J., Mehra, R., Körbling, M., Giralt, S., Gajewski, J., Donato, M., Cleary, K., Claxton, D., Braunschweig, I., Andersson, B., Anderlini, P., Champlin, R. Ann. Oncol. (1999) [Pubmed]
  5. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Przepiorka, D., Smith, T.L., Folloder, J., Khouri, I., Ueno, N.T., Mehra, R., Körbling, M., Huh, Y.O., Giralt, S., Gajewski, J., Donato, M., Cleary, K., Claxton, D., Braunschweig, I., van Besien, K., Andersson, B.S., Anderlini, P., Champlin, R. Blood (1999) [Pubmed]
  6. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Przepiorka, D., Phillips, G.L., Ratanatharathorn, V., Cottler-Fox, M., Sehn, L.H., Antin, J.H., LeBherz, D., Awwad, M., Hope, J., McClain, J.B. Blood (1998) [Pubmed]
 
WikiGenes - Universities